T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| 1 |
Rivian
RIVN
|
+$16.1B |
| 2 |
Apple
AAPL
|
+$6.15B |
| 3 |
NVIDIA
NVDA
|
+$5.7B |
| 4 |
Tesla
TSLA
|
+$4.7B |
| 5 |
Microsoft
MSFT
|
+$2.23B |
Top Sells
| 1 |
Visa
V
|
+$4.3B |
| 2 |
Meta Platforms (Facebook)
META
|
+$3.34B |
| 3 |
Morgan Stanley
MS
|
+$2.78B |
| 4 |
Global Payments
GPN
|
+$2.39B |
| 5 |
PayPal
PYPL
|
+$1.74B |
Sector Composition
| 1 | Technology | 27.48% |
| 2 | Healthcare | 16.09% |
| 3 | Consumer Discretionary | 15.75% |
| 4 | Communication Services | 12.37% |
| 5 | Financials | 10.68% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1351
Lamb Weston
LW
$7.86B
| $13.7M | ﹤0.01% |
215,585
-21,311
| -9% | -$1.35M |
|
|
GTM
1352
ZoomInfo Technologies
GTM
$3.72B
| $13.7M | ﹤0.01% |
212,700
+27,444
| +15% | +$1.76M |
|
1353
ePlus
PLUS
$1.97B
| $13.6M | ﹤0.01% |
251,928
-60
| -0% | -$3.23K |
|
|
LIAN
1354
DELISTED
LianBio American Depositary Shares
LIAN
| $13.4M | ﹤0.01% |
+2,242,389
| New | +$13.4M |
|
1355
Ambev
ABEV
$35.9B
| $13.4M | ﹤0.01% |
4,786,300
+75,700
| +2% | +$212K |
|
|
CCXI
1356
DELISTED
ChemoCentryx, Inc.
CCXI
| $13.4M | ﹤0.01% |
367,423
-9,199
| -2% | -$335K |
|
1357
Natera
NTRA
$23.1B
| $13.4M | ﹤0.01% |
143,021
-3,842
| -3% | -$359K |
|
1358
WEX
WEX
$5.82B
| $13.3M | ﹤0.01% |
94,992
+2,055
| +2% | +$289K |
|
1359
PENN Entertainment
PENN
$2.86B
| $13.3M | ﹤0.01% |
256,126
-188,818
| -42% | -$9.79M |
|
1360
Pinnacle West Capital
PNW
$10.5B
| $13.3M | ﹤0.01% |
187,834
-7,171
| -4% | -$506K |
|
1361
JD.com
JD
$47.7B
| $13.2M | ﹤0.01% |
188,402
-21,733
| -10% | -$1.52M |
|
1362
GeneDx Holdings
WGS
$3.56B
| $13.1M | ﹤0.01% |
88,865
+2,428
| +3% | +$357K |
|
1363
Invitation Homes
INVH
$18.5B
| $13M | ﹤0.01% |
287,807
+1,153
| +0.4% | +$52.3K |
|
1364
Immunocore
IMCR
$1.78B
| $13M | ﹤0.01% |
379,891
+17,865
| +5% | +$612K |
|
1365
Protagonist Therapeutics
PTGX
$3.66B
| $12.9M | ﹤0.01% |
377,132
-114,509
| -23% | -$3.92M |
|
1366
PVH
PVH
$3.9B
| $12.8M | ﹤0.01% |
120,222
-3,671
| -3% | -$392K |
|
1367
Molson Coors Class B
TAP
$9.57B
| $12.8M | ﹤0.01% |
275,265
-13,032
| -5% | -$604K |
|
1368
Sprott Physical Gold and Silver Trust
CEF
$6.61B
| $12.7M | ﹤0.01% |
715,877
-342,485
| -32% | -$6.08M |
|
1369
United Therapeutics
UTHR
$18.3B
| $12.7M | ﹤0.01% |
58,718
-1,516
| -3% | -$328K |
|
1370
Newell Brands
NWL
$2.48B
| $12.7M | ﹤0.01% |
580,288
-34,367
| -6% | -$751K |
|
1371
Genpact
G
$7.41B
| $12.6M | ﹤0.01% |
237,607
-5,925
| -2% | -$314K |
|
1372
Informatica
INFA
$7.55B
| $12.5M | ﹤0.01% |
+339,066
| New | +$12.5M |
|
1373
Canadian National Railway
CNI
$58.3B
| $12.3M | ﹤0.01% |
100,373
+39,390
| +65% | +$4.85M |
|
|
WHWK
1374
Whitehawk Therapeutics, Inc. Common Stock
WHWK
$93.8M
| $12.3M | ﹤0.01% |
508,892
+43,293
| +9% | +$1.05M |
|
1375
Credicorp
BAP
$21.1B
| $12.2M | ﹤0.01% |
99,597
-1,574,605
| -94% | -$192M |
|